

# Diagnostic Slide Session 2023 Case 9

Janna Shold, DO, PGY4 and Nelli Lakis, MD, MSc

The University of Kansas Medical Center




3901 Rainbow Blvd.


Kansas City, KS 66160


# Clinical History


- 62-year-old male with a history of mild Hemophilia A who presents with recurrent episodes of syncope


# Imaging













Differential diagnosis?





Olig2



GFAP

# Immunohistochemical Workup

## **Positive**

- GFAP
- Olig2

## **Negative**

- P53
- IDH1-R132H
- Synaptophysin
- Chromogranin
- NeuN
- BRAF V600E
- H3 K27M

## **Retained**

- H3 K27me3
- ATRX (subset)

# Ancillary Studies

- **TERT promoter mutation (TERT promoter -124C>T)**
- FISH for 1p & 19q shows no co-deletions
- FISH for EGFR shows no amplification
- MGMT promoter methylation is ABSENT

# Ancillary Studies

- AKT2 & EWSR1-PATZ1 fusions

## NGS TEST: RNA Exome Fusion Panel v1.0

STRUCTURAL VARIANTS: FUSION					
Gene	Transcripts	Genomic Location	Reads	Pathogenicity Assessment	Tier*
<i>EWSR1 - PATZ1</i> <i>e7 : e1</i>	NM_001163286.2 - NM_032052.2	chr22:29685737 - chr22: 31740542	54	Likely Pathogenic	Tier 3
<i>PATZ1 -</i> <i>NIPSNAP1</i> <i>e1 : e4</i>	NM_032052.2 - NM_003634.4	chr22:31740747 - chr22: 29961074	13	Uncertain Significance	Tier 3

\*Tier: Actionability Classification

### 1 - FUSION VARIANT INTERPRETATION

**Result:** 1 relevant variant is detected in this study.

**Summary:**

EWSR1-PATZ1 fusion was detected with a total of 54 reads, and is consistent with a recent study of 60 predominantly pediatric CNS neoplasms harboring PATZ1 fusions for which DNA methylation profiling defined a biologically distinct molecular class of histologically polyphenotypic neuroepithelial tumors [PMID: 34417833].

# Methylation Profile

- Methylation profile on the version 12.5 of Heidelberg classifier matches to neuroepithelial tumor with PATZ1 fusion with a high confidence score
  - EWSR1-PATZ1 fusion found on NGS is consistent with this methylation class

# Integrated Diagnosis


- Neuroepithelial tumor with PATZ1 fusion
  - TERT promoter mutation (TERT promoter -124C>T)
  - MGMT promoter methylation ABSENT
  - AKT2 R371H mutation

# Neuroepithelial tumor with PATZ1 fusion

*PATZ1* fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

[Karam T. Alhalabi](#), [Damian Stichel](#), [Philipp Sievers](#), [Heike Peterziel](#), [Alexandra Sturm](#), [Andrea Wittmann](#), [Martin Sill](#), [Natalie Jäger](#), [Pengbo Beck](#), [Kristian V. George](#), [George Jour](#), [Michael Delorenzo](#), [Allison M. Martin](#), [Adam Levy](#), [Nagma Da G. Gottardo](#), [Emmanuelle Uro-Coste](#), [Claude-Alain Maurage](#), [Catherine Goc](#), [Torsten Pietsch](#), ... [David T. W. Jones](#) ✉ [+ Show authors](#)

- Novel entity
- Histologically heterogeneous tumors of different grades
- Varied immunophenotypes



# Neuroepithelial tumor with PATZ1 fusion

- Median age at diagnosis 11 years
  - 74% under 18 years
- Located in supratentorial region but rarely in posterior fossa
- Intermediate prognosis
- Currently no therapies available for directly target alterations in EWSR1



# Patient Follow-Up

- Completed radiation therapy
- Continues temozolomide

# References

- Alhalabi KT, Stichel D, Sievers P, et al. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. *Acta Neuropathol.* 2021;142(5):841-857. doi: 10.1007/s00401-021-02354-8.
- Burel-Vandenbos F, Pierron G, Thomas C, et al. A polyphenotypic malignant paediatric brain tumour presenting a MN1-PATZ1 fusion, no epigenetic similarities with CNS High-Grade Neuroepithelial Tumour with MN1 Alteration (CNS HGNET-MN1) and related to PATZ1-fused sarcomas. *Neuropathol Appl Neurobiol.* 2020;46(5):506-509. doi: 10.1111/nan.12626.
- Siegfried A, Rousseau A, Maurage CA, et al. EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity. *Brain Pathol.* 2019;29(1):53-62. doi: 10.1111/bpa.12619.
- Tauziède-Espariat A, Chotard G, le Loarer F, et al. A novel LARGE1-AFF2 fusion expanding the molecular alterations associated with the methylation class of neuroepithelial tumors with PATZ1 fusions. *Acta Neuropathol Commun.* 2022;10(1):15. doi: 10.1186/s40478-022-01317-8.